CITIUS ONCOLOGY, INC.
For the period ended Sep 30, 2025. Filed Dec 23, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Dec 23, 2025
CTOR$0.55+7.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| 2025 | 2024 | |
|---|---|---|
| Revenues | $— | $— |
| Operating Expenses: | ||
| Research and development | 6,418,334 | 4,925,001 |
| General and administrative | 8,783,997 | 8,148,929 |
| Stock-based compensation – general and administrative | 8,320,419 | 7,498,817 |
| Total Operating Expenses | 23,522,750 | 20,572,747 |
| Operating loss | (23,522,750) | (20,572,747) |
| Other Income (Expense) | ||
| Interest income | 36,373 | — |
| Interest expense | (218,032) | — |
| Total Other Income (Expense), Net | (181,659) | — |
| Loss before Income Taxes | (23,704,409) | (20,572,747) |
| Income tax expense | 1,056,960 | 576,000 |
| Net Loss | $(24,761,369) | $(21,148,747) |
| Net Loss Per Share – Basic and Diluted | $(0.34) | $(0.31) |
| Weighted Average Common Shares Outstanding – Basic and Diluted | 73,267,969 | 68,053,607 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.